Overview Causes & Risks Symptoms, Stages & Types Tests & Diagnosis Your Prostate Cancer Care Team Treatment Remission & Recurrence Living With Support & Resources Appointment Prep Hormone Treatment for Prostate Cancer: What to Expect Medically Reviewed by Nazia Q Bandukwala, DO on May 27, 2024 Wri...
Hormone therapy for prostate cancer can cause bone thinning osteoporosis, which can lead to broken bones. However, treatment with bisphosphonates -- likeAredia,Fosamax, andZometa-- may help prevent this condition from developing, says Holden. ...
Mario Eisenberger. . Controversies in hormone treatment for prostate cancer. 2008:, 291-294. /Mario, Eisenberger. Controversies in hormone treatment for prostate cancer. 2008:, 291-294. /MarioEisenberger. Controversies in hormone treatment for prostate cancer. 2008:, 291-294. /...
If you or a loved one have been diagnosed with prostate cancer, you may be offered hormone therapy to treat it. Increasingly, hormone therapy is the treatment of choice, rather than surgery. Surgery to reduce hormone levels may only be offered if the cancer has spread to other areas or is...
Fargo agreed. "I don't think any doctors are going to make different decisions based on this single study," he said. "If your doctor has put you on this medication for yourprostate cancertreatment, you should continue it. Consult with your physician, but don't stop taking your medication...
Luteinizing hormone-releasing hormone (LHRH) analogues play a pivotal role in hormonal therapy regimens for the treatment of prostate cancer. Hormonal ther... H Akaza - 《Pharmacology》 被引量: 40发表: 2010年 Docetaxel re-treatment for metastatic hormone refractory prostate cancer Docetaxel re-treatm...
(AP) -- A new study links hormone therapy for prostate cancer with a higher risk of death in older men who've had serious heart problems. Ad Hormone therapy suppresses the amount of testosterone produced, in turn causing prostate tumors to shrink or grow more slowly. The treatment, involving...
International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. OBJECTIVE: To review pooled phase II data to identify features of different regimens of intermittent hormone therapy (IHT), developed to reduce the ...
For metastatic prostate cancer, androgen deprivation therapy (ADT) is the key strategy to control the disease. However, after 18–24 months of treatment, most patients will progress from metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) even...
We refer to this state of the disease as castration-resistant prostate cancer (CRPC). Because most of these tumours still depend on androgen-receptor signalling for growth, the terms androgen-independent or hormone-refractory are not appropriate.3 Only one treatment, docetaxel, is approved by the...